nanoRETE is an early stage company with the mission to replace current, suboptimal tuberculosis screening tests with a superior diagnostic tool that advances the market to single point of care. Completing commercialization will deliver a definitive diagnostic tool to be used in the management of public health.

nanoRETE was founded in 2011 by the Michigan Accelerator Fund I. Through SBIR funding from the Department of Defense (DoD) and private investment, the company has created a proprietary blood-based, lateral flow assay kit based on newly identified biomarkers which indicate the presence of TB infection. Early pre-clinical trial results have demonstrated comparable sensitivity and superior selectivity against the market standard with a greater than 80% reduction in test time, which translates directly to savings in laboratory labor burden.

The company is currently early stage in commercialization of the diagnostic platform.